Trial Profile
Shedding and immune response of rotavirus vaccine (RotaTeq)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2020
Price :
$35
*
At a glance
- Drugs Rotavirus W179-9 vaccine (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- 04 Nov 2020 Status changed from recruiting to completed.
- 17 Dec 2019 Results (N=301), showing shedding of RotaTeq vaccine indicates high uptake rate and prominence of G-type G1, published in the Vaccine
- 06 Jan 2015 New trial record